tiprankstipranks
Trending News
More News >
Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
US Market

Monopar Therapeutics Inc (MNPR) Stock Forecast & Price Target

Compare
520 Followers
See the Price Targets and Ratings of:

MNPR Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Monopar
Therapeutics Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MNPR Stock 12 Month Forecast

Average Price Target

$53.50
▲(51.77%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Monopar Therapeutics Inc in the last 3 months. The average price target is $53.50 with a high forecast of $76.00 and a low forecast of $40.00. The average price target represents a 51.77% change from the last price of $35.25.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","77":"$77","19.25":"$19.25","38.5":"$38.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$76.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,19.25,38.5,57.75,77],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.15,45.676923076923075,48.20384615384615,50.730769230769226,53.25769230769231,55.78461538461538,58.31153846153846,60.83846153846154,63.36538461538461,65.8923076923077,68.41923076923077,70.94615384615385,73.47307692307692,{"y":76,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.15,43.94615384615385,44.74230769230769,45.53846153846154,46.33461538461538,47.13076923076923,47.926923076923075,48.723076923076924,49.51923076923077,50.315384615384616,51.11153846153846,51.90769230769231,52.70384615384616,{"y":53.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.15,42.90769230769231,42.66538461538462,42.42307692307692,42.18076923076923,41.93846153846154,41.69615384615385,41.45384615384615,41.21153846153846,40.96923076923077,40.72692307692308,40.48461538461538,40.24230769230769,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.89,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$76.00Average Price Target$53.50Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on MNPR
Biren AminPiper Sandler
Piper Sandler
$76
Buy
115.60%
Upside
Reiterated
05/19/25
Piper Sandler Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
JonesTrading Analyst forecast on MNPR
Justin WalshJonesTrading
JonesTrading
Hold
Reiterated
05/14/25
JonesTrading Reaffirms Their Hold Rating on Monopar Therapeutics Inc (MNPR)
Brookline Capital Markets Analyst forecast on MNPR
Kumaraguru RajaBrookline Capital Markets
Brookline Capital Markets
$60$58
Buy
64.54%
Upside
Reiterated
05/13/25
Monopar Therapeutics (MNPR) PT Lowered to $58 at Brookline Capital MarketsBrookline Capital Markets analyst Raja Kumaraguru lowered the price target on Monopar Therapeutics (NASDAQ: MNPR) to $58.00 (from $60.00) while maintaining a Buy rating.
H.C. Wainwright Analyst forecast on MNPR
Sean Lee CFAH.C. Wainwright
H.C. Wainwright
$40
Buy
13.48%
Upside
Reiterated
04/01/25
Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating
Citi
$40
Buy
13.48%
Upside
Reiterated
03/31/25
Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook
Rodman & Renshaw Analyst forecast on MNPR
Elemer PirosRodman & Renshaw
Rodman & Renshaw
$50
Buy
41.84%
Upside
Initiated
10/11/24
Monopar Therapeutics initiated with a Buy at Rodman & RenshawMonopar Therapeutics initiated with a Buy at Rodman & Renshaw
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on MNPR
Biren AminPiper Sandler
Piper Sandler
$76
Buy
115.60%
Upside
Reiterated
05/19/25
Piper Sandler Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
JonesTrading Analyst forecast on MNPR
Justin WalshJonesTrading
JonesTrading
Hold
Reiterated
05/14/25
JonesTrading Reaffirms Their Hold Rating on Monopar Therapeutics Inc (MNPR)
Brookline Capital Markets Analyst forecast on MNPR
Kumaraguru RajaBrookline Capital Markets
Brookline Capital Markets
$60$58
Buy
64.54%
Upside
Reiterated
05/13/25
Monopar Therapeutics (MNPR) PT Lowered to $58 at Brookline Capital MarketsBrookline Capital Markets analyst Raja Kumaraguru lowered the price target on Monopar Therapeutics (NASDAQ: MNPR) to $58.00 (from $60.00) while maintaining a Buy rating.
H.C. Wainwright Analyst forecast on MNPR
Sean Lee CFAH.C. Wainwright
H.C. Wainwright
$40
Buy
13.48%
Upside
Reiterated
04/01/25
Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating
Citi
$40
Buy
13.48%
Upside
Reiterated
03/31/25
Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook
Rodman & Renshaw Analyst forecast on MNPR
Elemer PirosRodman & Renshaw
Rodman & Renshaw
$50
Buy
41.84%
Upside
Initiated
10/11/24
Monopar Therapeutics initiated with a Buy at Rodman & RenshawMonopar Therapeutics initiated with a Buy at Rodman & Renshaw
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Monopar Therapeutics Inc

1 Month
xxx
Success Rate
6/14 ratings generated profit
43%
Average Return
+5.39%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +5.39% per trade.
3 Months
xxx
Success Rate
6/14 ratings generated profit
43%
Average Return
+50.16%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +50.16% per trade.
1 Year
Sean Lee CFAH.C. Wainwright
Success Rate
8/14 ratings generated profit
57%
Average Return
+132.71%
reiterated a buy rating 2 months ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +132.71% per trade.
2 Years
xxx
Success Rate
9/14 ratings generated profit
64%
Average Return
+220.53%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +220.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MNPR Analyst Recommendation Trends

Rating
Nov 24
Jan 25
Mar 25
Apr 25
May 25
Strong Buy
4
4
3
4
5
Buy
1
3
4
4
2
Hold
0
0
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
7
8
9
9
In the current month, MNPR has received 7 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. MNPR average Analyst price target in the past 3 months is 53.50.
Each month's total comprises the sum of three months' worth of ratings.

MNPR Financial Forecast

MNPR Earnings Forecast

Next quarter’s earnings estimate for MNPR is -$0.53 with a range of -$0.71 to -$0.42. The previous quarter’s EPS was -$1.22. MNPR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.23% of the time in the same period. In the last calendar year MNPR has Preformed in-line its overall industry.
Next quarter’s earnings estimate for MNPR is -$0.53 with a range of -$0.71 to -$0.42. The previous quarter’s EPS was -$1.22. MNPR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.23% of the time in the same period. In the last calendar year MNPR has Preformed in-line its overall industry.
No data currently available

MNPR Sales Forecast

Next quarter’s sales forecast for MNPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. MNPR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year MNPR has Preformed in-line its overall industry.
Next quarter’s sales forecast for MNPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. MNPR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year MNPR has Preformed in-line its overall industry.

MNPR Stock Forecast FAQ

What is MNPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Monopar Therapeutics Inc’s 12-month average price target is 53.50.
    What is MNPR’s upside potential, based on the analysts’ average price target?
    Monopar Therapeutics Inc has 51.77% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MNPR a Buy, Sell or Hold?
          Monopar Therapeutics Inc has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Monopar Therapeutics Inc’s price target?
            The average price target for Monopar Therapeutics Inc is 53.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $76.00 ,the lowest forecast is $40.00. The average price target represents 51.77% Increase from the current price of $35.25.
              What do analysts say about Monopar Therapeutics Inc?
              Monopar Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of MNPR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis